Generate Biomedicines, Inc. (GENB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$17.17

From 52W high−15.90%

Volume1.40M

Market cap$2.20B

P/E (TTM)—

P/S (TTM)69.0x

Div yield—

Key dataSep 18, 2026

Open

$17.17

From 52W high

−15.90%

Volume

1.40M

Market cap

$2.20B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.7x

P/E (TTM)

—

RSI (14)

54.5

MomentumView details →

1D Return

+0.12%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.7x

EV/Sales

56.6x

P/S (TTM)

69.0x

P/B (TTM)

4.8x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−636.99%

EBITDA Margin

−653.71%

ROE (TTM)

−44.55%

ROA (TTM)

−36.17%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+55.89%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.12%

YTD Return

—

1Y Return

—

RSI (14)

54.5

vs 50D SMA

+9.52%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

8.30x

Quick Ratio

8.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

−2.30%

Beats (12Q)

0/12

Next Q EPS Est

−$0.56

Avg Surprise (4Q)

−70.04%

Rev Surprise

19.13%

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsNov 5, 2026 →

Latest newsMore news →

Generate Biomedicines Inc's post-IPO lock-up period is set to expire on Wednesday, allowing insiders, early investors, and major shareholders to sell shares from its $400 million IPO.26d ago

Generate Biomedicines Inc. reported its second quarter 2026 financial results, including cash, cash equivalents, and marketable securities of approximately $457.4 million as of June 30, 2026.45d ago

Similar companies

Oxford Lane Capital Corp.OXLCI Oxford Lane Capital Corp. 7.95% Notes due 2032OXLCG Oxford Lane Capital Corp. 5.00% Notes due 2027OXLCZ Columbia Acorn International InstACINX Oxford Lane Capital Corp. 6.75% Notes due 2031OXLCL T. Rowe Price Spectrum Moderate Allc InvTRPBX Find similar companies →

Latest newsMore news →

Generate Biomedicines Inc's post-IPO lock-up period is set to expire on Wednesday, allowing insiders, early investors, and major shareholders to sell shares from its $400 million IPO.26d ago Generate Biomedicines Inc. reported its second quarter 2026 financial results, including cash, cash equivalents, and marketable securities of approximately $457.4 million as of June 30, 2026.45d ago